YieldMax MSTR Option Income Strategy ETF vs TransMedics Group Inc — how do they compare? YieldMax MSTR Option Income Strategy ETF trades at $15.38 (market cap $1.06B), while TransMedics Group Inc trades at $81.29 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 2.6× YieldMax MSTR Option Income Strategy ETF's market cap, and TransMedics Group Inc is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax MSTR Option Income Strategy ETF for 30 Days and TransMedics Group Inc for 24 Days on average.
| MSTY | TMDX | |
|---|---|---|
Market Cap | $1.06B | $2.74B |
Volume | 2,402,888 | 949,331 |
Sector | Income / Options Overlay | Health |
52-Week High | $67.85 | $150.42 |
52-Week Low | $11.55 | $61.99 |
Typical Hold Time | 30 Days | 24 Days |
Enterprise Value | — | $3.13B |
Signals from Pluang's Aura AI — not financial advice
MSTY trades at $15.83, down 5.61% today amid bearish technical signals. The ETF shows mixed sentiment with Seeking Alpha rating it Hold despite a 100.32% annualized distribution rate. Recent articles highlight significant NAV erosion, with $10,000 investments declining to approximately $6,614 over six months according to 24/7 Wall Street analysis from July 2026.
The fund's high distribution strategy comes with substantial principal erosion risk. While weekly dividends provide income, the structural design returns investor capital as distributions. Analyst consensus remains cautious due to the fund's dependence on MSTR volatility and ongoing NAV decline, making this suitable only for sophisticated investors understanding the income-principal tradeoff.
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →